Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

 
This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*
share



Semantic enrichment by EKT
Journal part (EN)
Scientific article (EN)
2021 (EN)
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis (EN)
Barnes, Alex
Klebe, Sonja
Mountifield, Réme
Hall, Lesley-Ann
Hofmann, Dirk
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response. Keywords Ocrelizumab, inflammatory bowel disease, immunotherapy, colitis, esophagitis Ann Gastroenterol 2021; 34 (3): 447-448 (EN)
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Hellenic Society of Gastroenterology
Annals of Gastroenterology
Case Report
English
2021-05-05
http://www.annalsgastro.gr/index.php/annalsgastro/article/view/5762
Hellenic Society of Gastroenterology (EN)
1792-7463
1108-7471
Annals of Gastroenterology; Volume 34, No 3 (2021); 447 (EN)
Copyright (c) 2021 Annals of Gastroenterology (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)